Connection

Bart Rijnders to Drug Therapy, Combination

Back to Details
This is a "connection" page, showing publications Bart Rijnders has written about Drug Therapy, Combination.
Bart Rijnders
Connection Strength
0.121
Drug Therapy, Combination
  1. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. Lancet Gastroenterol Hepatol. 2019 04; 4(4):269-277.
    View in: PubMed
    Score: 0.071
  2. Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients. J Antimicrob Chemother. 2019 09 01; 74(9):2759-2766.
    View in: PubMed
    Score: 0.018
  3. Brief Report: High Need to Switch cART or Comedication With the Initiation of DAAs in Elderly HIV/HCV-Coinfected Patients. J Acquir Immune Defic Syndr. 2017 10 01; 76(2):193-199.
    View in: PubMed
    Score: 0.016
  4. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017 05; 4(5):e195-e204.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.